Article

Opening the Door, Staying Put: The Hong Kong Stock Exchange’s 2026 Listing Framework Reform

13 August 2026

Back

Home

Insights & News

Insights & News Details

The Stock Exchange of Hong Kong Limited (the “Exchange“) published a consultation paper on 13 March 2026 inviting the market to respond on proposed reforms intended to enhance the competitiveness of Hong Kong’s listing framework (the “Consultation Paper“). Following the consultation period, the Exchange published its conclusions on 24 July 2026, confirming that the proposed reforms would proceed, with a number of refinements made in light of the feedback received (the “Consultation Conclusions“). Three areas are covered, namely, the weighted voting rights (“WVR“) regime, pathway for overseas listed issuers and initial listing requirements and arrangements. These reforms represent the first of two planned phases of the Exchange’s competitiveness review. The Exchange has indicated that it will return to the second phase through further consultation at a future point.

This newsletter sets out the material dates and transitional arrangements potential listing applicants should be aware of, offers a quick reference guide for different categories of stakeholders, summarises the key proposals adopted under each reform area, highlights where the Exchange stayed put, and the next phase of reform.

Section 1: Effective date and transitional arrangement

The proposals adopted under the Consultation Conclusions took immediate effect upon publication on 24 July 2026. Applicants with an active listing application under Chapter 8 of the Main Board Listing Rules (the “LR”) as at that date may apply to the Exchange to amend their application to be considered instead for a listing under Chapter 8A (as an issuer with a WVR structure) and/or Chapters 18A or 18C (as a Biotech Company or Specialist Technology Company), without needing to withdraw and refile their application. Applicants that wish to make such changes prior to listing should approach the Exchange promptly through their sponsors.

Section 2: Quick Navigation

Given that these reforms affect market stakeholders differently, the table below directs applicants and issuers to the most relevant parts of Section 3 of this Newsletter.

If you are	Where to Focus on Section 3	Relevance
An issuer already listed on the Exchange	3.3(b)	The WVR ratio cap and economic interest relaxations do not extend to issuers already listed on the Exchange. For issuers reporting under the United States (the “US“) Generally Accepted Accounting Principles (the “US GAAP“) because of an existing US listing, two changes are relevant to ongoing reporting obligations: (i) the removal of the requirement to revert to HKFRS or IFRS upon a US delisting, and (ii) the removal of the auditor review requirement for the reconciliation statement, being the statement setting out the financial impact of material differences between financial statements prepared under US GAAP and those prepared under HKFRS or IFRS (the “Reconciliation Statement”).
A company planning a Hong Kong (“HK”) IPO	3.3(a); 3.3(d)	Applies to any new applicant regardless of WVR. Covers the codification of the ownership continuity requirement, the extension of the confidential filing option to all applicants, and the enhanced mechanism for the return of a listing application to sponsor (the “Return Mechanism”).
A company planning a HK IPO with a WVR structure	3.1(a); 3.1(b); 3.1(c); 3.3(a); 3.3(d)	Applicants should consider whether the lowered financial thresholds, the 20:1 ratio cap pathway with its economic interest conditions. As with any new applicant, applicants must also satisfy the codified ownership continuity requirement and may separately choose to file confidentially.
A US/overseas-listed company considering a HK secondary listing	3.2(a); 3.2(b); 3.3(c); 3.3(d)	Lowered secondary listing thresholds apply to WVR and non-WVR issuers alike. Issuers adopting US GAAP should note the expanded allowance and removal of the reversion requirement. As a new applicant to the Exchange, applicants may also choose to file confidentially and note the enhanced Return Mechanism covering disclosure of professional parties and the revised moratorium timing on a returned application.
A Biotech/Specialist Technology Company applicant (the “Eligible Specialist Company”)	3.1(c); 3.3(c)	Applicants in this category may elect the specialist chapter route even if financially eligible under Chapter 8 of LR. This does not create a shortcut into a WVR listing, since an Eligible Specialist Company seeking a WVR structure remains fully subject to the Chapter 8A safeguards, including the suitability assessment.
A sponsor or adviser	All of 3	Advisory role spans over all applicant types. Sponsors or advisors should familiarise themselves with the transitional arrangements, the filing and Return Mechanism changes.

Section 3: Three Areas of Reform

The table below summarises, for each of the three reform areas, the existing requirements, the key proposals adopted, and the Exchange’s underlying rationale.

Subject	Existing requirements	Principal proposals for adoption	Rationale
3.1 WVR
(a) Financial eligibility for listing	Market capitalisation: WVR Test (A) at least HK$40 billion; or WVR Test (B) at least HK$10 billion; and revenue at least HK$1 billion revenue for the most recent audited financial year.	Lower market capitalisation thresholds: WVR Test (A) is lowered to at least HK$20 billion; while WVR Test (B) is lowered to at least HK$6 billion, and the revenue threshold lowered to at least HK$600 million.	HK’s WVR regime was introduced at a time when few comparable exchanges had an established WVR framework to benchmark against. In the absence of such precedents, the Exchange adopted relatively high financial eligibility thresholds to pre-emptively mitigate the risks associated with WVR structures. The lowest revised threshold, HK$6 billion, still exceeds the HK$4 billion bar set for non-WVR large-cap issuers by a wide margin, which a buffer the Exchange is relying on to keep investor protection intact.
(b) Voting power and economic interest	WVR ratio cap of 10:1.	Applicants with a market capitalisation of at least HK$40 billion at the time of listing may list with a higher WVR ratio cap of 20:1.	Under the current LR, an issuer cannot increase the proportion of its share capital represented by WVR shares after listing. The 20:1 ratio cap will accordingly not be extended to existing listed WVR issuers. The Exchange also considers the HK$40 billion market capitalisation threshold sufficient to mitigate the risks arising from the widened gap between voting control and economic ownership, with existing safeguards providing adequate protection for minority shareholders. The Exchange retains discretion to address an “extreme case of non-conformance with corporate governance norms,” with further guidance to follow via future listing decisions.
(b) Voting power and economic interest	WVR shareholding percentage of at least 10%, with a lower percentage accepted only where defined conditions are met.	Conditions for a lower percentage: at the time of initial listing, WVR beneficiaries must collectively hold (a) at least 5% of the applicant’s total issued share capital; and (b) an amount worth at least HK$4 billion.	The HK$4 billion floor for minimum economic interest is intended to align WVR beneficiaries’ interests with those of non-WVR shareholders and increase certainty for market users. Even in an extreme case, i.e. HK$80 billion market cap issuer where a beneficiary holds only 5% economic interest but 51% of voting power, the Exchange considers this absolute dollar floor sufficient to preserve that alignment. No ongoing post-listing requirement is imposed, consistent with most major WVR markets the existing rules already prevent an issuer from increasing WVR beneficiaries’ voting control after listing. The Exchange retains absolute discretion to refuse listing in extreme cases of non-conformance with corporate governance norms.
(c) Innovativeness	Applicants seeking a WVR listing must demonstrate that they are an “innovative” company.	A WVR listing applicant may now demonstrate innovativeness via two refined routes: Route A: adoption of technologies that are either novel in themselves or essential to the novelty of its core business; or Route B: success attributable to a new business model applied to its core business, where the model is enabled by technology, that technology need not itself be novel or essential to the novelty of the core business.	The Exchange reiterated that the refinements are not an expansion of the WVR regime’s scope, but a formalisation of existing vetting practice with added objective, measurable criteria. WVR structures remain confined to high-growth companies with high investment potential. Characteristics which an innovative company would normally be expected to present (the “Innovative Characteristics”) are assessed only at listing, with no ongoing requirement post-listing. Both routes must show the novelty characteristic that the applicant’s operations differ from conventional industry practice. In addition: Route A applicants must show more than one of: (i) research and development (the “R&D”) as a significant contributor to expected value (with R&D expenses disclosed); (ii) success attributable to IP; (iii) or outsized market capitalisation/intangible asset value relative to tangible assets. Route B applicants must show all of (i) revenue in compound annual growth rate with at least 30% over the track record period; and (ii) a relatively prominent industry position.
	Presumption that applicants who are Eligible Specialist Company are innovative.	Additional groups of applicants seeking to list under Chapter 8 of the LR are presumed to meet requirements to demonstrate that it is an innovative company: (a) Qualified Biotech Applicants, operate in the biotech industry, are primarily engaged in the R&D of at least one core product and have commercialised it, have continued R&D of the core product for the 12 months prior to listing, and own the IP rights to the core product; and (b) Qualified Specialist Technology Applicants, are primarily engaged in the R&D of, and have commercialised, specialist technology product(s) within an acceptable sector of a specialist technology industry, and meet the R&D expenditure percentage test designed for a commercial company under Chapter 18C of LR.
	Applicant must have previously received meaningful third-party investment from at least one sophisticated investor.	New guidance narrows and clarifies the “sophisticated investor” concept underpinning the external validation requirement.	Investor sophistication remains a case-by-case determination, evaluated by factors such as the investor’s track record, expertise, and financial capacity, including net assets, assets under management, or portfolio size, with no carve-outs for specific investor categories. Where financial capacity is the relevant metric, it must be measured twice: (i) within six months before the investment agreement is signed, and (ii) again within six months before the listing application is filed.
3.2 Issuers listed overseas
(a) Qualification requirements for secondary listings	WVR secondary listing applicants must satisfy the same financial eligibility thresholds as primary WVR listings (see 3.1(a) above), together with a two-year compliant track record of good regulatory compliance on the New York Stock Exchange LLC, Nasdaq Stock Market LLC or London Stock Exchange plc (the “Qualifying Exchange”).	To lower the financial eligibility thresholds for a WVR secondary listing to align with those proposed for primary WVR listings. WVR Test A: expected market capitalisation of at least HK$20 billion at the time of listing; or WVR Test B: expected market capitalisation of at least HK$6 billion and revenue of at least HK$600 million for the most recent audited financial year.	The Exchange’s secondary listing regime relies on the regulatory framework of the issuer’s primary listing market, on the premise that the majority of trading in the issuer’s securities continues to take place there. If that majority of trading migrates to the Exchange instead, the issuer will be required to convert to a primary listing, at which point exemptions available to secondary listed issuers will cease to apply.
(a) Qualification requirements for secondary listings	A non-WVR overseas issuer must satisfy either Criteria A, at least HK$3 billion market capitalisation with a five-year track record on a qualifying or recognised stock exchange, or Criteria B, at least HK$10 billion market capitalisation with a two-year track record, but only on a Qualifying Exchange.	Criteria A’s HK$3 billion threshold is retained. Criteria B’s threshold is lowered from HK$10 billion to HK$6 billion.	Secondary listings rely heavily on the primary market’s own regulatory framework. A sufficiently high market cap and track record together demonstrate issuer quality. Criteria B stays limited to Qualifying Exchanges, given their investor protection standards are closest to the Exchange, justifying its shorter track record requirement.
(b) Conversion to primary listing	Existing guidance to support issuers moving from a secondary listing to either a dual primary or full primary listing.	The Exchange will issue clearer, more accessible guidance covering the shift from secondary to primary listing status, setting out the practical steps issuers need to complete.	The underlying requirements for this conversion are not changing. The Exchange is instead restructuring how those requirements are presented, so issuers can more easily follow the process and understand what compliance involves.
(c) Further facilitative measures for issuers listed overseas	N/A	The Exchange will continue to review the suggestions raised by respondents on further measures to support issuers listed overseas, working with relevant stakeholders as it does so, and will launch a public consultation only if it considers this necessary.
3.3 Initial listing requirements and listing arrangements
(a) Ownership continuity and control	An applicant must show that, throughout the relevant look back window, it operated as a single integrated business under a shareholder capable of exerting substantial management influence.	The Exchange will write its existing guidance into rule form. Under the codified test, an applicant satisfies the requirement if it can show no material change in management influence occurred between the start of the most recent audited financial year and the point immediately before listing, even where the controlling shareholder changed during that window.	This is not a new substantive requirement. It puts an existing, long-standing practice into rule form, without changing how the Exchange evaluates continuity of management influence. The Exchange takes the view that turning established practice into a codified rule gives applicants greater clarity and predictability, while it continues to hold the discretion to refuse an application where it identifies genuine attempts to disguise a change of control.
(b) Financial reporting standards	Applicant listed/ to be listed in the US seeking dual listing in HK may apply for a waiver to adopt US GAAP.	Subject to specified conditions, US GAAP would be expanded to subsidiary companies of US-listed parent and companies with substantial US business operations.	Issuers who will be adopting the US GAAP would be required to set out in their listing documents the material differences in the Reconciliation Statement. Such issuers would also be required to include a Reconciliation Statement in each of their annual and interim reports post-listing.
	US GAAP reports need to revert to preparing financial statements using HKFRS or IFRS after it delists from the US.	Requirement removed	N/A
	Reconciliation Statement for unaudited financial reports must be reviewed by auditors.	Requirement removed	N/A
(c) Commercialised biotech and specialist technology applicants	A Biotech Company or Specialist Technology Company that satisfies any Rule 8.05 financial eligibility test under Chapter 8 of the LR must currently list via the ordinary route, rather than under the specialist Chapters.	A Biotech Company or Specialist Technology Company that satisfies one or more of the Rule 8.05 eligibility tests, will be permitted to choose the applicable specialist chapter route instead of the ordinary route, even where it is financially eligible to list via Chapter 8 of the LR.	Allowing this choice does not create a shortcut into a WVR listing. An Eligible Specialist Company that wishes to list with a WVR structure remains fully subject to the Chapter 8A LR safeguards, including its suitability assessment, so the change does not lower the bar for WVR applicants.
(d) Confidential filing and enhanced Return Mechanism	Under the current rules, only eligible secondary listing applicants, Eligible Specialist Companies may file confidentially. Other applicants may do so only if granted a case-by-case waiver.	Every new listing applicant, regardless of category, will be able to choose the non-public filing route.	The current category-based approach reflects that only a limited set of applicants may withhold publication at filing. Since nearly every issuer holds commercially sensitive information or trade secrets it may legitimately want to shield at that early stage, opening this option to all applicants puts companies of every size and business type on equal footing.
	Where an application is not substantially complete and is returned, only the sponsor’s identity is currently published on the Exchange’s website.	On a return of a listing application, the Exchange will also publish the names and roles of the other professional parties involved in preparing the application materials: the sponsor, the company’s legal advisers, the sponsor’s legal advisers, the reporting accountants and independent auditors, industry consultants, any other experts who consented to inclusion of their work in the application, and any promoters. The reasons for the return will also be published.	Naming these parties is not meant to assign fault or impose a penalty. Preparing application materials is a joint effort among the applicant, sponsor, and other professional advisers. The purpose is transparency about who was involved, and to encourage all parties to work together to meet the expected standard, without changing how regulatory responsibility is currently allocated.
	The eight-week period during which a returned applicant may not resubmit its listing application currently runs from the date of the listing division’s decision to return that application.	The starting point of that eight-week period will shift away from the date of the original return decision. It will instead begin on whichever is relevant: (i) the date the window to invoke any applicable review procedure closes, or, (ii) if the applicant does pursue a review, the date that review process concludes.	A return decision should only be treated as final once any review the applicant chooses to pursue has run its course. An applicant who does not seek a review has its moratorium start once the window to do so closes, while an applicant who does seek a review has its moratorium start once that review concludes and the return is upheld. Either way, every applicant serves the same full eight-week period once the return becomes final.

Section 4: Where the Exchange stayed put

Not every proposal was adopted as suggested, and applicants should note where the Exchange chose to preserve the existing framework. On the WVR ratio cap, the Exchange declined to lower the HK$40 billion market capitalisation threshold that gates access to the 20:1 ratio, and declined to extend the ratio, to issuers already listed with a WVR structure. A suggested carve out reserving the lowered Test B thresholds for Route A applicants only was not taken up, on the basis that the thresholds are meant to ensure a minimum scale of investor support rather than to differentiate between types of innovation. On issuers listed overseas, the Exchange retained Criteria A and Criteria B for secondary listing eligibility as two separate sets of criteria rather than merging them, maintaining the higher bar reserved for issuers on Qualifying Exchanges. On initial listing requirements, more fundamental alternatives to the ownership continuity requirement, including replacing it with a substantive anti packaging test or removing it altogether in favour of the listing suitability assessment, were not adopted.

Section 5: What’s next

Respondents also raised several themes falling outside the scope of the current proposals, which the Exchange has flagged for a further phase of reform. These include modernising continuing obligations for listed issuers, broadening access for mid cap and growth stage companies, and facilitating listings in high growth sectors. The Exchange has confirmed it will separately review the regulatory framework for GEM and its specialist listing regimes, including the special purpose acquisition company framework and the specialist technology company route, with a further consultation paper to follow.

This round of reform introduces a number of changes that affect large, well-established issuers, particularly those already listed on major overseas exchanges and commercialised biotech or specialist technology companies. It will be interesting to see what the phase two reform will entail.

This newsletter is prepared for general information purposes only and does not constitute legal advice. It is not exhaustive and does not cover all matters which issuers may need to consider. For further information, please contact the authors of this newsletter or your usual contact at CFN Lawyers LLP for assistance.